REGULATORY

MOF Pitches Off-Year Re-Pricing for “All Products” Including Patented Meds, Eyes Adjustment Rate Revision Too

October 9, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Finance (MOF) on October 8 presented its proposal on the scope of the planned “off-year” drug re-pricing next April, calling for considering a blanket revision on all products including patent-protected medicines to reduce financial burdens on Japanese…

To read the full story

MOF Panel Issues FY2021 Budget Recommendation, Ups Tone on All-Product Drug Re-Pricing
November 26, 2020
List of MOF’s Proposals Related to Pharmaceuticals
October 9, 2020
MOF Calls for Setting New Targets for Generic and Biosimilar Use
October 9, 2020

REGULATORY

Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026
MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…